Table 1. Summary of patient treatment response.

Disease status, previous treatments, treatment administered, extent of clinical and molecular remission, duration of response, overall survival, and expected survival were tabulated. Survival times are calculated from first treatment with alemtuzumab. Mean time between relapses was 6 months. CR, complete remission; PR, partial response (decrease in white blood cell counts); CNS, central nervous system; Allo, allogeneic; N/A, not applicable.

PatientDisease status
before epigenetic
therapy
Previous
treatment
Treatment
administered
Clinical
remission
Molecular
remission
Duration of
response
Overall
survival time
Expected
survival*
1First relapseCVP (cyclophosphamide,
vincristine, prednisone)
Alemtuzumab,
cladribine
CRYes16 months34.3 months4 months
Second relapseAlemtuzumab,
cladribine
Alemtuzumab,
cladribine
PRN/A11.6 months
Third relapseAlemtuzumab,
cladribine
Alemtuzumab,
brentuximab vedotin
PRN/A6.7 months to death,
persistent disease
2First relapseAlemtuzumab
(6 months CR)
Alemtuzumab,
cladribine, vorinostat
CRYes5.3 months17 months7.5 –
10 months
Second relapseAlemtuzumab,
cladribine, vorinostat
Alemtuzumab,
cladribine, vorinostat
PRN/A2 months
Third relapseAlemtuzumab,
cladribine, vorinostat
Alemtuzumab,
cladribine, vorinostat
PRN/A3.7 months to death,
persistent disease
3Initial presentationN/AAlemtuzumab,
cladribine
PRN/A5.7 months5.7 months20 months
4Initial presentationN/AAlemtuzumab,
cladribine
CRYes13.3 months14.8 months20 months
First relapseAlemtuzumab,
cladribine
Alemtuzumab,
cladribine
PRN/A1.5 months to death,
persistent disease,
CNS hemorrhage
5Initial presentationN/AAlemtuzumab,
cladribine, vorinostat
CRYes6.3 months15.3 months20 months
First relapse with
skin involvement
Alemtuzumab,
cladribine, vorinostat
Alemtuzumab,
cladribine, romidepsin
PRN/A4 months—blood
Second relapse with
skin involvement
Alemtuzumab,
cladribine, romidepsin
Brentuximab vedotinPRN/A5 months to Allo
transplant, death,
persistent disease
6Initial presentationN/AAlemtuzumab,
cladribine
CRYes0.8 months to
Allo transplant
0.8+ monthsN/A
7First relapseAlemtuzumab
(0.3 months)
Alemtuzumab,
cladribine, valproic acid
CRYes12 months to Allo
transplant referral
12+ months4 months
8First relapseAlemtuzumab
(16 months)
Alemtuzumab,
cladribine
CRYes6.7 months23.7+ months7.5 –
10 months
Second relapseAlemtuzumab,
cladribine
Alemtuzumab,
cladribine
CRYes1+ month

*Expected survival without transplant (5).